All good - they always under report their guidance and report higher They are anticipating 10% YoY growth and 22-25% EBITDA margin which is quite achievable Population growth in a year + increased access can easily > 10% revenue growth
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025